Alpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® (Benzgalantamine) and Cholinesterase Inhibitors at Upcoming Scientific Meetings
Reuters
Oct 15, 2025
<a href="https://laohu8.com/S/ACOGD">Alpha Cognition Inc.</a> to Present New Clinical Data on ZUNVEYL® (Benzgalantamine) and Cholinesterase Inhibitors at Upcoming Scientific Meetings
Alpha Cognition Inc., a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, has announced plans to present new clinical data on cholinesterase inhibitors and its product ZUNVEYL® (benzgalantamine) at two upcoming scientific meetings. The company will share insights at the American Society of Consultant Pharmacists (ASCP) Annual Meeting scheduled for October 23-25, 2025, and the Neuroscience Education Institute (NEI) Annual Congress scheduled for November 6-9, 2025. The presentations will include poster sessions on topics such as acetylcholinesterase inhibitors and psychotropic medication use, persistence of therapy in Alzheimer's disease and related dementias, methodologies for switching between acetylcholinesterase inhibitors, and the effects of these treatments on sleep and mortality in Alzheimer's disease. The results are set to be presented at these future meetings.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014774412) on October 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.